Navigation Links
BioBDx to Present at the 2012 BioPharm America and AdvaMed MedTech Conferences in Boston

PLYMOUTH MEETING, Pa., Sept. 17, 2012 /PRNewswire/ -- BioBehavioral Diagnostics (BioBDx) announced today that Calvin Sumner M.D., chief medical officer and SVP of clinical development, will be presenting at the BioPharm America Conference taking place September 19-21, 2012 and Byron Hewett, chairman and CEO, will be presenting at the AdvaMed MedTech Conference taking place October 1-3, 2012, both in Boston, MA.

BioBDx manufactures and markets the Quotient® System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is the objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD). 

Dr. Sumner and Mr. Hewett will provide a company overview and update on the Quotient System during their presentations:

 Event:BioPharm America 2012 ConferenceDate: Friday, September 21, 2012 Time: 10:25 am ETLocation:Hancock Room; Westin Boston WaterfrontEvent:AdvaMed 2012 MedTech ConferenceDate: Tuesday, October 2, 2012 Time: 11:10 am ETLocation:Room 051; Boston Convention & Exhibition Center 

About the Quotient® ADHD TestThe Quotient® ADHD Test measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD.  Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity.  Patients may be re-assessed periodically at follow-up visits to guide treatment plans.  The clinician integrates the Quotient® report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information please visit:

About BioBehavioral Diagnostics CompanyBioBDx manufactures and markets the Quotient System, a tool that aids in the objective and accurate assessment of neural control functions related to deficits in inhibitory control.  We are dedicated to providing physicians, parents and patients high-value information to guide personalized strategies and enhance quality of life for patients with ADHD.  Our vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine.  Founded in 2006, BioBDx is a privately held company.

Contacts:BioBDxByron Hewett

Chairman and Chief Executive Officer


Byron_Hewett@BioBDx.comMedia/Investors:Tiberend Strategic Advisors, Inc.

Claire Sojda


SOURCE BioBehavioral Diagnostics Company
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
2. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
3. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
4. Representatives Betty McCollum (MN) and Steven LaTourette (OH) to Receive USGS Coalition Leadership Award
5. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
6. Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
7. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
8. Isis Pharmaceuticals To Present At Two Upcoming Investor Conferences
9. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
10. Onyx Pharmaceuticals To Present At Upcoming Investor Conferences
11. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies would ... named to Deloitte's 2015 Technology Fast 500 list of the fastest growing companies ... FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by as ...
(Date:11/24/2015)... , Nov. 24, 2015 HemoShear ... on discovering drugs for metabolic disorders, announced today ... to its Board of Directors (BOD). Mr. Watkins ... of Human Genome Sciences (HGS), and also served ... Jim Powers , Chairman and CEO ...
(Date:11/24/2015)... ... ... Whitehouse Laboratories is pleased to announce that it has completed construction on ... to basic USP 61, USP 62 and USP 51 testing specific to raw materials ... micro testing performed by one supplier. Management has formally announced that the ...
(Date:11/23/2015)...   Ceres, Inc . (Nasdaq: CERE ), ... the fiscal year ended August 31, 2015 and provided ... --> During fiscal year 2015, Ceres ... with a better balance of yield, energy and nutrition. ... several leading crop input providers and made significant progress ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
Breaking Biology News(10 mins):